Latest news with #PeterBains
Mint
4 days ago
- Business
- Mint
Syngene International share price gains 2% despite weak Indian stock markets: Should you buy or sell the stock?
Stock Market Today: Syngene International gained more than 2% in the intraday trades on Friday despite weak Indian stock markets. Should you buy or sell? Syngene International had reported Q1 results on Wednesday. The Q1 performance marked a decent start to the new financial year 2026. The adjusted reported net profit at ₹ 87 crore increased 59% year-on-year compared to ₹ 54 crore in the year-ago quarter (excluding the exceptional item of ₹ 21 crore (net of tax) in Q1 FY25 relating to the final settlement from an insurance claim). The revenue from operations was up 11% year-on-year to Rs. 875 crore, while the reported EBITDA was up by 19% year-on-year, with the reported EBITDA margin at 25%. Peter Bains, Managing Director and CEO of Syngene International, said that he expects the momentum to continue and expects to meet the annual guidance. The primary driver of this momentum was the continued conversion of pilot programs into longer-term contracts within the Research Services division, as per Bains. In our Biologics manufacturing division, the Unit III facility in Bengaluru has received the USFDA clearance, while the Bayview facility in the U.S. is expected to commence operations in the second half of FY26. While Bains said that he remains mindful of ongoing macroeconomic factors, we maintain a confident outlook. The company, being primarily into services, may see a lesser impact of proposed tariffs. Jefferies India Pvt Ltd, after Q1 results, has said that Syngene's 1QFY26 earnings beat their estimates as inventory adjustment is set to kick in from the second or third quarter. The start of the US biologics facility in the second half, as per Jefferies, is to keep margins under check. Further management as per Jefferies has reiterated FY26 guidance despite the strong Q1, indicating near-term headwinds. Further In the past few quarters, Syngene has made senior hires at overseas pharma hubs to strengthen its business development efforts; however, Jefferies expects benefits to be realized only from FY27/28. After a sharp 37.5% decline over 103 days, Syngene has been consolidating in a tight box for the past 66 sessions, signaling a pause before its next move. The current session is showing strong momentum and could be a precursor to a breakout, said ANSHUL JAIN, Head of Research at LAKSHMISHREE A sustained move above 690 will confirm the breakout and likely lead to a sharp bounce. The immediate target lies near the 50% Fibonacci retracement level of the previous fall, placed around 775. Traders should watch for volume confirmation to ride the breakout with conviction, said Jain Disclaimer: The views and recommendations made above are those of individual analysts or brokerage companies and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
6 days ago
- Business
- Time of India
Syngene Q1 profit up 59% to Rs 87 crore
Representative image BENGALURU: Syngene International, a subsidairy of Biocon , reported a 59 per cent year-on-year increase in profit after tax to Rs 87 crore in the first quarter ended June 2025, aided by revenue growth and a tax benefit from the transfer of gratuity funds to an employee trust. Revenue from operations rose 11 per cent to Rs 875 crore during the period. Ebitda grew 19 per cent year-on-year to Rs 224 crore, with margins improving to 25 per cent from 23 per cent a year earlier. CEO Peter Bains said the growth was led by the conversion of pilot programs into long-term contracts in the Research Services division. The company also progressed operations at its Biologics Unit III facility in Bengaluru and prepared for the launch of its Bayview site in the US later this year. It commissioned a new peptide laboratory during the quarter. The company said it underwent over 20 client and regulatory audits in Q1, including a USFDA GCP inspection of its Human Pharmacology Unit with no observations. Its Biologics facility received an Establishment Inspection Report with a Voluntary Action Indicated outcome. CFO Deepak Jain said operating Ebitda margins held around 24 per cent, supported by revenue growth and cost optimisation. Syngene said it remains on track to meet its full-year guidance. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
News18
6 days ago
- Business
- News18
Syngene PAT rises 61 pc to Rs 87 cr in Jun qtr
Agency: PTI New Delhi, Jul 23 (PTI) Syngene International on Wednesday reported a 61 per cent increase in its consolidated profit after tax to Rs 87 crore in the first quarter ended June 30, 2025. The company posted a profit after tax (PAT) of Rs 54 crore in the April-June quarter of the last fiscal. Revenue from operations rose to Rs 875 crore during the first quarter as compared with Rs 790 crore in the year-ago period, the contract research, development and manufacturing organisation (CRDMO) said in a regulatory filing. 'Continued conversion of pilot programmes into longer-term contracts within our research services business was the main driver underpinning this momentum," Syngene International Managing Director and Chief Executive Officer Peter Bains said. 'While we remain mindful of ongoing macroeconomic factors, we maintain a confident outlook," he added. Shares of the company ended 0.5 per cent up at Rs 679.65 apiece on the BSE. PTI MSS MSS SHW Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Upturn
6 days ago
- Business
- Business Upturn
Syngene International Q1 Results: Revenue grows 11% YoY to Rs 790 crore, Net profit jumps 59% YoY
Syngene International Limited reported strong financial results for the quarter ended June 30, 2025 (Q1 FY26), led by higher revenue and improved margins. For the quarter, the company's revenue from operations rose 11% year-on-year (YoY) to ₹875 crore, compared to ₹790 crore in Q1 FY25. Reported revenue, including other income, stood at ₹892 crore, up 10% YoY. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) came in at ₹224 crore, growing 19% from ₹188 crore last year. The EBITDA margin improved to 25% from 23% YoY, driven by revenue growth and cost optimization. Net profit (PAT) surged 59% to ₹87 crore from ₹54 crore in the same quarter last year. The PAT margin expanded to 10% from 7% YoY. Key Financials: YoY comparison Metric Q1 FY25 Q1 FY26 YoY Change (%) Revenue from operations (₹ Cr) 790 875 ↑ 11% Reported revenue (₹ Cr) 808 892 ↑ 10% EBITDA (₹ Cr) 188 224 ↑ 19% EBITDA margin (%) 23 25 ↑ 200 bps Net profit (PAT) (₹ Cr) 54 87 ↑ 59% PAT margin (%) 7 10 ↑ 300 bps Commenting on the results, Peter Bains, Managing Director and CEO, highlighted that the performance was in line with expectations, supported by continued conversion of pilot programs into longer-term contracts in the Research Services business and progress in the Biologics manufacturing division. Deepak Jain, CFO, noted that the quarter's profitability also benefitted from a tax credit, and the company maintained a strong balance sheet to invest in capabilities and technology. Other business highlights included the successful completion of USFDA inspections, inauguration of a state-of-the-art peptide laboratory, and recognition by TIME and Statista as one of the world's most sustainable companies. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
India Gazette
27-06-2025
- Business
- India Gazette
Indian CRDMOs benefiting from diversification by global pharmaceutical companies: Jefferies
New Delhi [India], June 27 (ANI): Indian CRDMOs (Contract Research and Development and Manufacturing Organizations) are seeing growing interest from global pharmaceutical companies, according to a recent report by Jefferies. The report highlighted that Big Pharma companies are increasingly diversifying their manufacturing and research operations geographically, and Indian companies with expertise in small molecule development are well placed to benefit. It said 'Big Pharma is diversifying geographically, benefiting Indian CRDMOs with small molecule expertise'. The report highlighted some major pharma companies (Including Piramal Pharma, Syngene, Laurus Labs, Cohance, Gland Pharma). The report said that these companies highlighted that many of the ongoing projects are still in the clinical stages, so growth may be uneven. There is also a rising demand for antibody-drug conjugate (ADC)-related CDMO services, and Indian companies are exploring opportunities in that space. The report also mentioned that GLP-1, a class of diabetes and obesity drugs, could become an important growth driver for generic CMOs from 2026. Piramal Pharma is targeting 13-15 per cent CAGR in sales over the next 4-5 years in its India consumer health and complex hospital generics businesses. While the company expects subdued sales from its largest CDMO product in FY26 due to destocking, overall segment revenue is likely to remain flat due to better utilisation at overseas facilities and a recovery expected in FY27. Syngene's growth in FY26 is expected to be in the mid-single digits, mainly due to destocking of Librela, its largest product. The company expects growth to pick up to low double digits after that. Its new management, led by Peter Bains, is focusing on growth and acquiring US biologics capacities. However, the overseas unit will have lower margins and may take time to break even. Laurus is currently handling seven active projects from global pharma clients, which account for 50-60 per cent of its new projects in the past two years. About 70-80 per cent of the company's CDMO division sales come from commercial molecules. Many of the ongoing projects involve breakthrough therapies that typically have lower failure rates. The company has invested Rs 4 billion in animal health and Rs 1.5 billion in AgChem, with another Rs 1 billion planned for animal health. It aims to achieve peak sales of 1.5 times the capex from these investments by FY28-29. Cohance is recovering from the impact of destocking that affected its AgChem and SpecChem business over the past 18 months. The company is planning to launch a new product in the third quarter of FY26 and bring in new customers in the division. Gland Pharma is expanding its GLP-1 cartridge fill-finish capacity from 40 million to 140 million units by the end of next year. The company's new bulk line will be flexible for use across both GLP-1 and insulin products. The report outlined that while near-term growth may be uneven due to destocking, most companies expect a strong rebound and long-term momentum. (ANI)
